Evidence on the use of progesterone in menopausal hormone therapy
- PMID:29630427
- DOI: 10.1080/13697137.2018.1455657
Evidence on the use of progesterone in menopausal hormone therapy
Abstract
A need exists for a regulatory agency-approved hormone therapy (HT) with naturally occurring hormones combining progesterone (P4) and estradiol (E2), since no single product contains both endogenous hormones. Many women choose HT with P4 and millions of women around the world are using unapproved, poorly regulated compounded HT. The use of natural P4 in HT results, for the most part, in favorable outcomes without deleterious effects, as shown in clinical studies of postmenopausal women. Importantly, P4 used in HT prevents endometrial hyperplasia from estrogens while helping relieve vasomotor symptoms and improving quality-of-life measures. Additionally, risk of venous thromboembolism and breast cancer does not appear to increase with use of P4 plus estrogens as shown with synthetic progestins plus estrogens in large observations studies, and no detrimental effects of P4 in HT have been found on outcomes related to cardiovascular disease or cognition. A regulatory agency-approved HT with naturally occurring E2/P4 could be an option for the millions of women who desire a bioidentical product and/or are exposed to potential risks of inadequately studied and under-regulated compounded HT.
Keywords: Progesterone; hormone therapy; menopause.
Similar articles
- 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF.Mirkin S, et al.Maturitas. 2015 May;81(1):28-35. doi: 10.1016/j.maturitas.2015.02.266. Epub 2015 Mar 9.Maturitas. 2015.PMID:25835751Clinical Trial.
- The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, Chowdhury R, Franco OH, Muka T.Oliver-Williams C, et al.Hum Reprod Update. 2019 Mar 1;25(2):257-271. doi: 10.1093/humupd/dmy039.Hum Reprod Update. 2019.PMID:30508190
- Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins.Graham S, Archer DF, Simon JA, Ohleth KM, Bernick B.Graham S, et al.Gynecol Endocrinol. 2022 Nov;38(11):891-910. doi: 10.1080/09513590.2022.2118254. Epub 2022 Sep 8.Gynecol Endocrinol. 2022.PMID:36075250Review.
- Long-term hormone therapy for perimenopausal and postmenopausal women.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J.Marjoribanks J, et al.Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.Cochrane Database Syst Rev. 2017.PMID:28093732Free PMC article.Review.
- Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.L'Hermite M.L'Hermite M.Climacteric. 2017 Aug;20(4):331-338. doi: 10.1080/13697137.2017.1291607. Epub 2017 Mar 16.Climacteric. 2017.PMID:28301216Review.
Cited by
- Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).Lobo RA, Liu J, Stanczyk FZ, Constantine GD, Pickar JH, Shadiack AM, Bernick B, Mirkin S.Lobo RA, et al.Menopause. 2019 Jul;26(7):720-727. doi: 10.1097/GME.0000000000001306.Menopause. 2019.PMID:30694918Free PMC article.Clinical Trial.
- Update on Menopausal Hormone Therapy for Fracture Prevention.Stepan JJ, Hruskova H, Kverka M.Stepan JJ, et al.Curr Osteoporos Rep. 2019 Dec;17(6):465-473. doi: 10.1007/s11914-019-00549-3.Curr Osteoporos Rep. 2019.PMID:31741221Free PMC article.Review.
- Progestins and the Risk of Breast Cancer.Mastorakos G, Iatrakis G, Zervoudis S, Syropoulou S.Mastorakos G, et al.Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):90-100. doi: 10.4183/aeb.2021.90.Acta Endocrinol (Buchar). 2021.PMID:34539915Free PMC article.Review.
- Role of estrogen in women's Alzheimer's disease risk as modified by APOE.Valencia-Olvera AC, Maldonado Weng J, Christensen A, LaDu MJ, Pike CJ.Valencia-Olvera AC, et al.J Neuroendocrinol. 2023 Feb;35(2):e13209. doi: 10.1111/jne.13209. Epub 2022 Nov 24.J Neuroendocrinol. 2023.PMID:36420620Free PMC article.Review.
- Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.Liu JH, Black DR, Larkin L, Graham S, Bernick B, Mirkin S.Liu JH, et al.Menopause. 2020 Dec;27(12):1388-1395. doi: 10.1097/GME.0000000000001631.Menopause. 2020.PMID:32842052Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources